OTCMKTS:PVCT Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis → Does this make you sick? (From Allegiance Gold) (Ad) Free PVCT Stock Alerts $0.19 0.00 (0.00%) (As of 05/20/2024 ET) Add Compare Share Share Today's Range$0.19▼$0.2050-Day Range$0.14▼$0.2252-Week Range$0.06▼$0.22Volume587,374 shsAverage Volume129,063 shsMarket Capitalization$79.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Provectus Biopharmaceuticals alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Provectus Biopharmaceuticals Stock (OTCMKTS:PVCT)Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.Read More PVCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PVCT Stock News HeadlinesMay 14, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual MeetingApril 18, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor CancersApril 16, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value CreationMarch 27, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal SodiumMarch 12, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and VaccinesMarch 7, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual MeetingFebruary 29, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual MeetingFebruary 23, 2024 | finance.yahoo.comProvectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces First Quarter 2024 Conference CallFebruary 15, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces First Quarter 2024 Conference CallFebruary 14, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Engages irlabs for Investor Relations ServicesFebruary 14, 2024 | globenewswire.comProvectus Biopharmaceuticals Engages irlabs for Investor Relations ServicesDecember 18, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine AdjuvantNovember 19, 2023 | morningstar.comProvectus Biopharmaceuticals Inc PVCTNovember 15, 2023 | finanznachrichten.deProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous MelanomaNovember 15, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous MelanomaNovember 13, 2023 | finanznachrichten.deProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal MelanomaNovember 13, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal MelanomaNovember 6, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNovember 2, 2023 | benzinga.comProvectus Algae Enters Into Livestock Methane Reduction Space Commissioning First Demonstration Biomanufacturing PlantAugust 7, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingAugust 1, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 CongressJune 28, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue SarcomasJune 3, 2023 | finance.yahoo.comPVCT - Provectus Biopharmaceuticals, Inc.May 12, 2023 | chron.comProvectus: Q1 Earnings SnapshotSee More Headlines Receive PVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:PVCT Previous SymbolNYSEMKT:PVCT CUSIPN/A CIK315545 Webwww.provectusbio.com Phone(866) 594-5999Fax866-998-0005Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,100,000.00 Net Margins-470.05% Pretax Margin-470.22% Return on EquityN/A Return on Assets-188.18% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$560,000.00 Price / Sales142.34 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-9.50Miscellaneous Outstanding Shares419,520,000Free Float365,823,000Market Cap$79.71 million OptionableNot Optionable Beta0.69 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Dominic Rodrigues C.F.A. (Age 55)CFA, Chief Operations Consultant & Vice Chairman of the Board Comp: $75kDr. Eric A. Wachter (Age 61)Co-Founder & CTO Comp: $174.19kMs. Heather Raines CPA (Age 57)Chief Financial Officer Comp: $83.33kKey CompetitorsBioXcel TherapeuticsNASDAQ:BTAICue BiopharmaNASDAQ:CUEAffimedNASDAQ:AFMDAntibe TherapeuticsOTCMKTS:ATBPDSELLAS Life Sciences GroupNASDAQ:SLSView All Competitors PVCT Stock Analysis - Frequently Asked Questions How have PVCT shares performed in 2024? Provectus Biopharmaceuticals' stock was trading at $0.0960 at the start of the year. Since then, PVCT stock has increased by 97.9% and is now trading at $0.19. View the best growth stocks for 2024 here. Are investors shorting Provectus Biopharmaceuticals? Provectus Biopharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 142,600 shares, an increase of 127.8% from the April 15th total of 62,600 shares. Based on an average trading volume of 320,200 shares, the days-to-cover ratio is presently 0.4 days. View Provectus Biopharmaceuticals' Short Interest. What other stocks do shareholders of Provectus Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), Cytori Therapeutics (CYTX), (DARA) (DARA), Energy Transfer (ET), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB) and MaxLinear (MXL). How do I buy shares of Provectus Biopharmaceuticals? Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PVCT) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Clinton Backing Biden Replacement???The Freeport SocietyThe #1 Crypto for AIWeiss RatingsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.